Md Belal Hossain, Hubert Wong, Mohsen Sadatsafavi, Victoria J Cook, James C Johnston, Mohammad Ehsanul Karim
{"title":"High-Dimensional Disease Risk Score for Dealing With Residual Confounding Bias in Estimating Treatment Effects With a Survival Outcome.","authors":"Md Belal Hossain, Hubert Wong, Mohsen Sadatsafavi, Victoria J Cook, James C Johnston, Mohammad Ehsanul Karim","doi":"10.1002/pds.70172","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Health administrative databases often contain no information on some important confounders, leading to residual confounding in the effect estimate. We aimed to explore the performance of high-dimensional disease risk score (hdDRS) to deal with residual confounding bias for estimating causal effects with survival outcomes.</p><p><strong>Methods: </strong>We used health administrative data of 49 197 individuals in British Columbia to examine the relationship between tuberculosis infection and time-to-development of cardiovascular disease (CVD). We designed a plasmode simulation exploring the performance of eight hdDRS methods that varied by different approaches to fit the risk score model and also examined results from high-dimensional propensity score (hdPS) and traditional regression adjustment. The log-hazard ratio (log-HR) was the target parameter with a true value of log(3).</p><p><strong>Results: </strong>In the presence of strong unmeasured confounding, the bias observed was -0.11 for the traditional method and -0.047 for the hdPS method. The bias ranged from -0.051 to -0.058 for hdDRS methods when risk score models were fitted to the full cohort and -0.045 to -0.049 when risk score models were fitted only to unexposed individuals. All methods showed comparable standard errors and nominal bias-eliminated coverage probabilities. With weak unmeasured confounding, hdDRS and hdPS produced approximately unbiased estimates. Our data analysis, after addressing residual confounding, revealed an 8%-11% higher CVD risk associated with tuberculosis infection.</p><p><strong>Conclusions: </strong>Our findings support the use of selected hdDRS methods to address residual confounding bias when estimating treatment effects with survival outcomes. In particular, the hdDRS method using rate-based risk score modeling on unexposed individuals consistently exhibited the least bias. However, the hdPS method showed comparable performance across most evaluated scenarios. We share reproducible R codes to facilitate researchers' adoption and further evaluation of these methods.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 7","pages":"e70172"},"PeriodicalIF":2.4000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229743/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.70172","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Health administrative databases often contain no information on some important confounders, leading to residual confounding in the effect estimate. We aimed to explore the performance of high-dimensional disease risk score (hdDRS) to deal with residual confounding bias for estimating causal effects with survival outcomes.
Methods: We used health administrative data of 49 197 individuals in British Columbia to examine the relationship between tuberculosis infection and time-to-development of cardiovascular disease (CVD). We designed a plasmode simulation exploring the performance of eight hdDRS methods that varied by different approaches to fit the risk score model and also examined results from high-dimensional propensity score (hdPS) and traditional regression adjustment. The log-hazard ratio (log-HR) was the target parameter with a true value of log(3).
Results: In the presence of strong unmeasured confounding, the bias observed was -0.11 for the traditional method and -0.047 for the hdPS method. The bias ranged from -0.051 to -0.058 for hdDRS methods when risk score models were fitted to the full cohort and -0.045 to -0.049 when risk score models were fitted only to unexposed individuals. All methods showed comparable standard errors and nominal bias-eliminated coverage probabilities. With weak unmeasured confounding, hdDRS and hdPS produced approximately unbiased estimates. Our data analysis, after addressing residual confounding, revealed an 8%-11% higher CVD risk associated with tuberculosis infection.
Conclusions: Our findings support the use of selected hdDRS methods to address residual confounding bias when estimating treatment effects with survival outcomes. In particular, the hdDRS method using rate-based risk score modeling on unexposed individuals consistently exhibited the least bias. However, the hdPS method showed comparable performance across most evaluated scenarios. We share reproducible R codes to facilitate researchers' adoption and further evaluation of these methods.
期刊介绍:
The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report.
Particular areas of interest include:
design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;
comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;
methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;
assessments of harm versus benefit in drug therapy;
patterns of drug utilization;
relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.